A partial agonist of PPAR prevents paclitaxel-induced peripheral neuropathy in mice, by inhibiting neuroinflammation
BRITISH JOURNAL OF PHARMACOLOGY(2024)
摘要
Background and PurposeChemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of paclitaxel, affecting 30-50% of patients. Increased survival and concern with patients' quality of life have encouraged the search for new tools to prevent paclitaxel-induced neuropathy. This study presents the glitazone 4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-N-phenylbenzene-sulfonamide (TZD-A1) as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR gamma), its toxicological profile and effects on paclitaxel-induced CIPN in mice.Experimental ApproachInteractions of TZD-A1 with PPAR gamma were analysed using in silico docking and in vitro reporter gene assays. Pharmacokinetics and toxicity were evaluated using in silico, in vitro and in vivo (C57Bl/6 mice) analyses. Effects of TZD-A1 on CIPN were investigated in paclitaxel-injected mice. Axonal and dorsal root ganglion damage, mitochondrial complex activity and cytokine levels, brain-derived neurotrophic factor (BDNF), nuclear factor erythroid 2-related factor 2 (Nrf2) and PPAR gamma, were also measured.Key ResultsDocking analysis predicted TZD-A1 interactions with PPAR gamma compatible with partial agonism, which were corroborated by in vitro reporter gene assays. Good oral bioavailability and safety profile of TZD-A1 were shown in silico, in vitro and in vivo. Paclitaxel-injected mice, concomitantly treated with TZD-A1 by i.p. or oral administration, exhibited decreased mechanical and thermal hypersensitivity, effects apparently mediated by inhibition of neuroinflammation and mitochondrial damage, through increasing Nrf2 and PPAR gamma levels, and up-regulating BDNF.Conclusion and ImplicationsTZD-A1, a partial agonist of PPAR gamma, provided neuroprotection and reduced hypersensitivity induced by paclitaxel. Allied to its safety profile and good bioavailability, TZD-A1 is a promising drug candidate to prevent and treat CIPN in cancer patients.
更多查看译文
关键词
chemotherapy,chronic pain,glitazone,mice,neuroinflammation,taxane
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要